Use of secreted leukoproteinase inhibitor slpi as a prognostic marker for diabetic nephropathy dn

A protease inhibition, diabetic nephropathy technology, applied in disease diagnosis, biological testing, analysis of materials, etc., can solve the problem of DN lack of renal prognostic markers and other problems, and achieve the effect of predicting prognosis

Active Publication Date: 2022-05-24
NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention provides the use of secretory leukocyte protease inhibitor SLPI in the preparation of diabetic nephropathy DN prognostic markers, so as to solve the problem in the prior art that DN still lacks suitable renal prognostic markers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of secreted leukoproteinase inhibitor slpi as a prognostic marker for diabetic nephropathy dn
  • Use of secreted leukoproteinase inhibitor slpi as a prognostic marker for diabetic nephropathy dn
  • Use of secreted leukoproteinase inhibitor slpi as a prognostic marker for diabetic nephropathy dn

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Methodology for screening prognostic markers combining transcriptomic profiling and clinical indicators

[0023] (1) Acquisition of discovery queue

[0024] The cohort used for transcriptome sequencing in the present invention comes from the prospective DN cohort of Nanjing General Hospital and National Clinical Research Center of Nephrology. Among them, the conditions for DN patients to enter the group: a) age ≥ 18 years old; b) patients with type 2 diabetes (WHO diagnostic criteria) accompanied by DN admitted to the Nanjing General Hospital of Nanjing Military Region and the National Clinical Research Center for Kidney Diseases diagnosed by renal biopsy , excluding other concomitant renal diseases; c) signed informed consent; d) on the basis of complete routine pathological examination, with renal tissue micro-separation; e) at least 1 year follow-up, at least 2 eGFR follow-up points per year; DN was included in the group 61 patients. Clinical data such as renal tis...

Embodiment 2

[0030] Application of SLPI as a prognostic marker for DN

[0031] (1) RT-PCR

[0032] The renal tissue paraffin specimens of DN patients were sectioned to LEICA laser microseparation special sections, freshly prepared xylene for dewaxing, dehydrated with gradient alcohol, and then the renal tubular tissue was separated by laser microseparation, and the tubular tissue was extracted with the FFPE RNA extraction kit purchased from QIAGEN Company. The total RNA obtained from , was determined by a two-step method: the first step was reverse transcription, and the mRNA was reverse transcribed to synthesize cDNA according to the kit instructions. The reaction conditions were: 25°C, 10min, 37°C, 120min, 85°C, 5min; Step 2: Real-time PCR reaction, using SLPI and 18s as primers, the reaction conditions are: 95℃, 30s, 95℃, 5s, 60℃, 34s, cycle 40 times, 95 ℃, 15s, 60℃, 1min, 95℃, 15s, record and observe the amplification curve and dissolution curve, determine the amplification product as...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the use of secreted leukocyte protease inhibitor SLPI as a prognostic marker of diabetic nephropathy DN. The present invention confirms through research: the expression of SLPI in renal tubular epithelial cells of DN patients increases, and the expression in urine also increases, and is significantly correlated with the decline slope of glomerular filtration rate (eGFR) of DN patients, which can predict the decline rate of patients with DN. prognosis. The inventors found that the mRNA and protein levels of SLPI in the renal tubules of DN patients were significantly increased by detecting the renal tissue sections and urine of DN patients, and the expression level of SLPI in urine increased in parallel with the renal protein level, and could effectively predict the prognosis of DN patients. And better than serum creatinine or proteinuria.

Description

technical field [0001] The invention belongs to the technical field of gene biological preparations, in particular to the application of a secreted leukocyte protease inhibitor SLPI in the field of diabetic nephropathy DN. Background technique [0002] Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes. With the increasing prevalence of diabetes in my country, the incidence of DN also increases. Investigations show that DN has surpassed glomerulonephritis and become the primary cause of chronic kidney disease (CKD) in hospitalized patients in my country. Survey data in the United States in the past 20 years show that under the background of effective control of important complications of diabetes, such as cardiovascular and cerebrovascular events, the incidence of end-stage renal disease (ESRD) caused by diabetes is not obvious. The diagnosis of DN also depends on clinical diagnosis and pathological diagnosis, and the treatment is m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2333/8107G01N2800/34G01N2800/52
Inventor 蒋松李申秦卫松刘志红
Owner NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap